Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Pre-Mkt 05-18 07:24:57 EDT

2.16

-0.17

-7.30%

盘前2.20

+0.04+1.85%

07:12 EDT

High2.30	Low2.14	Vol570.98K
Open2.29	D1 Closing2.33	Amplitude6.87%
Mkt Cap198.46M	Tradable Cap86.12M	Total Shares91.88M
T/O1.25M	T/O Rate1.43%	Tradable Shares39.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":2.16,"timestamp":1778875200000,"preClose":2.33,"halted":0,"volume":570981,"hourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.16,"latestTime":"07:12 EDT","volume":574,"amount":1248.189978,"timestamp":1779102773174,"change":0.04,"changeRate":0.018519,"amplitude":0.023148},"delay":0,"changeRate":-0.0729613733905579,"floatShares":39871400,"shares":91879177,"eps":-0.422618,"marketStatus":"Pre-Mkt","change":-0.17,"latestTime":"05-18 07:24:57 EDT","open":2.29,"high":2.3,"low":2.14,"amount":1251973.0805643,"amplitude":0.06867,"askPrice":2.39,"askSize":100,"bidPrice":2.16,"bidSize":16,"shortable":3,"etf":0,"ttmEps":-0.422618,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.16,"latestTime":"07:12 EDT","volume":574,"amount":1248.189978,"timestamp":1779102773174,"change":0.04,"changeRate":0.018519,"amplitude":0.023148},"postHourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.16,"latestTime":"18:34 EDT","volume":10219,"amount":22570.0135,"timestamp":1778884499218,"change":0.04,"changeRate":0.018519,"amplitude":0.03287},"volumeRatio":1.308865876071618},"requestUrl":"/m/hq/s/CNTX/tweets","defaultTab":"tweets","newsList":[{"id":"2636933020","title":"Context Therapeutics Secures Full Rights to Antibody Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2636933020","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636933020?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:20","pubTimestamp":1779103242,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) has issued an update. On May 14, 2026, Context Therapeutics amended its 2024 exclusive license agreement with BioA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-secures-full-rights-to-antibody-assets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-secures-full-rights-to-antibody-assets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","CNTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636271790","title":"Context Therapeutics enters license agreement amendment with BioAtla","url":"https://stock-news.laohu8.com/highlight/detail?id=2636271790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636271790?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:54","pubTimestamp":1779101659,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-enters-license-agreement-amendment-with-bioatla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-enters-license-agreement-amendment-with-bioatla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX","LENZ","BK4539","BK4007","BK4139","BCAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700022","title":"Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636700022?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:47","pubTimestamp":1779101229,"startTime":"0","endTime":"0","summary":"Context Therapeutics amended its exclusive license agreement with BioAtla for CT-202, eliminating all future milestone and royalty obligations.The amendment requires a USD 4.5 million upfront payment, with a final USD 2 million payment due by Aug. 1, 2026, in exchange for a fully paid-up, non-terminable license.Phase 1 initiation for the CT-202 trial is expected in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1Kk0v1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CNTX","BCAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636227490","title":"Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2636227490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636227490?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABZWSH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007","BK4139","BCAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636227200","title":"Context Therapeutics - Announces Buyout of Ct-202 Future Milestones and Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2636227200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636227200?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABZWSH3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNTX","BCAB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022773","title":"Context Therapeutics: Amendment Removes All Future Milestone and Royalty Obligations Owed by Company for Ct-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022773?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABZWSH3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNTX","BCAB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022740","title":"Context Therapeutics - to Pay $4.5 Mln Upfront and $2.0 Mln by Aug 1, 2026 for Ct-202 License","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022740?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABZWSH3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","CNTX","BCAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634443969","title":"Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634443969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634443969?lang=en_us&edition=fundamental","pubTime":"2026-05-10 10:00","pubTimestamp":1778378418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Context Therapeutics (CN...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tenaya-therapeutics-tnya-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tenaya-therapeutics-tnya-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CNTX","BLSX","BK4585","BLSG","BK4139","BK4581","BK4539","BK4112","BK4137","LU0029874061.USD","LU0128526141.USD","XBI","BK4007","TNYA","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633486443","title":"Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486443","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633486443?lang=en_us&edition=fundamental","pubTime":"2026-05-08 13:33","pubTimestamp":1778218401,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryContext Therapeutics Inc CNTX.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633214692","title":"Context Therapeutics (CNTX) Gets a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633214692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633214692?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:15","pubTimestamp":1778152554,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Paul Jeng maintained a Buy rating on Context Therapeutics yesterday and set a price target of $5.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/context-therapeutics-cntx-gets-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/context-therapeutics-cntx-gets-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699171","title":"Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633699171?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:00","pubTimestamp":1778112051,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS) and Context Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BLSX","BLSG","BK4137","BK4007","LU0128526141.USD","MLYS","BK4585","BK4112","BK4581","LU0029874061.USD","XBI","CNTX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633157221","title":"Context Therapeutics Q1 net loss widens 90% to $8.68 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633157221","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633157221?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:50","pubTimestamp":1778100607,"startTime":"0","endTime":"0","summary":"Context Therapeutics posted a net loss of USD 8.68 million for the three months ended March 31, 2026, widening 90% year over year.Operating loss widened 69% to USD 9.34 million as research and development expense more than doubled to USD 7.02 million.General and administrative expense rose 13% to USD 2.33 million, while interest income fell 46% to USD 520,139.Cash and cash equivalents totaled USD 54.5 million, expected to fund operations into mid-2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL1b0t6b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633315730","title":"Context Therapeutics Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633315730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633315730?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:38","pubTimestamp":1778099924,"startTime":"0","endTime":"0","summary":"Context Therapeutics Q1 net loss widens on higher R&D costsOverviewUS biopharma developer's Q1 net loss widened yr/yr on higher R&D expensesCompany expects cash position to fund operations into mid-20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J1H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633154044","title":"Context Therapeutics - Cash and Cash Equivalents of $54.5 Mln as of March 31, 2026 Expected to Fund Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2633154044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633154044?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:18","pubTimestamp":1778098684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA1R7YSX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633615411","title":"Context Therapeutics Inc. Q1 Basic EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2633615411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633615411?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:18","pubTimestamp":1778098684,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXB0315F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640246","title":"Context Therapeutics settles governance lawsuit with mootness fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632640246?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:44","pubTimestamp":1777668268,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Context Therapeutics ( ($CNTX) ). On March 11, 2026, the Delaware Court of Chancery approved a consent judgment...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-settles-governance-lawsuit-with-mootness-fee?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-settles-governance-lawsuit-with-mootness-fee?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX","BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647855","title":"Context Therapeutics litigation ends with $850,000 mootness fee paid by provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647855","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647855?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:08","pubTimestamp":1777666132,"startTime":"0","endTime":"0","summary":"Delaware Chancery Court on March 11, 2026 entered consent judgment in stockholder class action filed Feb. 4, 2026 against Context Therapeutics and its directors.Judgment found charter provisions on three-year director terms and for-cause removal invalid and unenforceable.Context filed certificate of correction March 11, 2026 removing invalid provisions, triggering dismissal with prejudice while court retained jurisdiction over mootness fee.Court on April 30, 2026 ordered USD 850,000 mootness fee to plaintiff counsel, without reviewing entitlement or amount.Third-party service provider paid fee May 1, 2026 under letter agreement; case closure tied to quorum at June 24, 2026 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL7LfWTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631252561","title":"Context Therapeutics Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2631252561","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631252561?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:07","pubTimestamp":1777493225,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc  expected to post a loss of12cents a share - Earnings Preview Context Therapeutics Inc CNTX.OQ CNTX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL8N41C3AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628784523","title":"Context Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784523","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784523?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:30","pubTimestamp":1776457819,"startTime":"0","endTime":"0","summary":"Context Therapeutics scheduled 2026 annual stockholder meeting for June 24, 2026 in virtual format.Vote set on election of seven director nominees to serve until 2027 annual meeting.Ballot includes ratification of CohnReznick as independent registered public accounting firm for fiscal 2026.Shareholders to consider charter amendment to raise authorized common shares to 300,000,000 from 200,000,000.Proposal also seeks approval to adjourn meeting if needed to secure additional votes on authorized-share increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLxG0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625094657","title":"Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2625094657","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625094657?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649641,"startTime":"0","endTime":"0","summary":"Neogen named Jennifer Evans Stacey as chief legal and compliance officer, appointing her as board secretary.Stacey most recently served as chief legal and compliance officer, secretary at Galera Therapeutics.Her prior senior roles include chief legal officer posts across life sciences organizations, including The Wistar Institute, Antares Pharma, Auxilium Pharmaceuticals.Stacey also serves on board of Context Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLLbZsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","NEOG","BK4198","LU2211817866.USD","HALO","BK4007","BK4139","CNTX","GRTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0924},{"period":"1month","weight":-0.1394},{"period":"3month","weight":-0.0609},{"period":"6month","weight":0.8621},{"period":"1year","weight":1.88},{"period":"ytd","weight":0.4694}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.188281},{"month":2,"riseRate":0.2,"avgChangeRate":-0.080088},{"month":3,"riseRate":0.6,"avgChangeRate":-0.010229},{"month":4,"riseRate":0.4,"avgChangeRate":-0.001309},{"month":5,"riseRate":0.6,"avgChangeRate":0.21913},{"month":6,"riseRate":0.75,"avgChangeRate":0.233367},{"month":7,"riseRate":0.5,"avgChangeRate":-0.057392},{"month":8,"riseRate":0.75,"avgChangeRate":0.057821},{"month":9,"riseRate":0.5,"avgChangeRate":0.000078},{"month":10,"riseRate":0.75,"avgChangeRate":0.018618},{"month":11,"riseRate":0.6,"avgChangeRate":-0.036732},{"month":12,"riseRate":0.4,"avgChangeRate":-0.161685}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}